| Literature DB >> 27638417 |
Jeannete Zurita1, Pedro Barba2, David Ortega-Paredes3, Marcelo Mora2, Sebastián Rivadeneira4.
Abstract
The spread of pandemic Staphylococcus aureus clones, mainly methicillin-resistant S. aureus (MRSA), must be kept under surveillance to assemble an accurate, local epidemiological analysis. In Ecuador, the prevalence of the USA300 Latin American variant clone (USA300-LV) is well known; however, there is little information about other circulating clones. The aim of this work was to identify the sequence types (ST) using a Multiple-Locus Variable number tandem repeat Analysis 14-locus genotyping approach. We analyzed 132 S. aureus strains that were recovered from 2005 to 2013 and isolated in several clinical settings in Quito, Ecuador. MRSA isolates composed 46.97% (62/132) of the study population. Within MRSA, 37 isolates were related to the USA300-LV clone (ST8-MRSA-IV, Panton-Valentine Leukocidin [PVL] +) and 10 were related to the Brazilian clone (ST239-MRSA-III, PVL-). Additionally, two isolates (ST5-MRSA-II, PVL-) were related to the New York/Japan clone. One isolate was related to the Pediatric clone (ST5-MRSA-IV, PVL-), one isolate (ST45-MRSA-II, PVL-) was related to the USA600 clone, and one (ST22-MRSA-IV, PVL-) was related to the epidemic UK-EMRSA-15 clone. Moreover, the most prevalent MSSA sequence types were ST8 (11 isolates), ST45 (8 isolates), ST30 (8 isolates), ST5 (7 isolates) and ST22 (6 isolates). Additionally, we found one isolate that was related to the livestock associated S. aureus clone ST398. We conclude that in addition to the high prevalence of clone LV-ST8-MRSA-IV, other epidemic clones are circulating in Quito, such as the Brazilian, Pediatric and New York/Japan clones. The USA600 and UK-EMRSA-15 clones, which were not previously described in Ecuador, were also found. Moreover, we found evidence of the presence of the livestock associated clone ST398 in a hospital environment.Entities:
Keywords: Epidemic clones; MLVA typing; MRSA; MSSA
Mesh:
Substances:
Year: 2016 PMID: 27638417 PMCID: PMC9427608 DOI: 10.1016/j.bjid.2016.08.006
Source DB: PubMed Journal: Braz J Infect Dis ISSN: 1413-8670 Impact factor: 3.257
Patient characteristics from whom MRSA and MSSA have been recovered.
| MRSA (%) | MSSA (%) | Total (%) | Clones | |
|---|---|---|---|---|
| Male | 44 (51.8%) | 41 (48.2%) | 85 (64.4%) | USA300-LV (23) |
| Female | 18 (38.3%) | 29 (61.7%) | 47 (35.6%) | USA300-LV (14) |
| Mean (y) | 38.5 | 48.9 | 43.7 | |
| 0–17 | 13 (68.42%) | 6 (31.58%) | 19 (14.39%) | USA300-LV (8) |
| 18–50 | 22 (53.66%) | 19 (46.34%) | 41 (31.06%) | USA300-LV (13) |
| 51–90 | 22 (40%) | 33 (60%) | 55 (41.67%) | USA300-LV (14) |
| N.D. | 5 (29.41%) | 12 (70.59%) | 17 (12.88%) | USA300-LV (2) |
| Skin and soft tissue | 19 (82.61%) | 4 (17.39%) | 23 (17.42%) | USA300-LV (13) |
| Blood | 27 (31.39%) | 59 (68.60%) | 86 (65.15%) | USA300-LV (19) |
| Respiratory tract | 5 (62.50%) | 3 (37.50%) | 8 (6.06%) | USA300-LV (1) |
| Bone | 4 (80%) | 1 (20%) | 5 (3.79%) | USA300-LV (1) |
| Others | 7 (70%) | 3 (30%) | 10 (7.57%) | USA300-LV (3) |
Clones identified in this study.
Number of susceptible isolates according to the sequence type (ST).
| ST | MSSA (no. of isolates) | MRSA (no. of isolates) | Gentamicin | Ciprofloxacin | Erythromycin | Clindamycin | Tetracycline | Rifampicin | Trimethoprim-sulfamethoxazole | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MSSA | MRSA | MSSA | MRSA | MSSA | MRSA | MSSA | MRSA | MSSA | MRSA | MSSA | MRSA | MSSA | MRSA | |||
| 5 | 7 | 3 | 6 | 1 | 7 | 1 | 2 | 0 | 7 | 1 | 4 | 3 | 7 | 2 | 7 | 3 |
| 8 | 11 | 44 | 11 | 41 | 11 | 40 | 9 | 37 | 10 | 43 | 10 | 43 | 11 | 44 | 11 | 38 |
| 15 | 1 | 0 | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – |
| 22 | 6 | 1 | 4 | 1 | 6 | 1 | 5 | 1 | 6 | 1 | 6 | 1 | 6 | 1 | 6 | 1 |
| 25 | 1 | 0 | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – |
| 30 | 8 | 1 | 8 | 0 | 8 | 1 | 3 | 1 | 8 | 1 | 7 | 1 | 8 | 1 | 8 | 1 |
| 34 | 2 | 0 | 2 | – | 2 | – | 1 | – | 1 | – | 2 | – | 2 | – | 2 | – |
| 45 | 8 | 1 | 8 | 0 | 7 | 0 | 4 | 0 | 5 | 1 | 7 | 1 | 7 | 0 | 8 | 0 |
| 81 | 2 | 0 | 2 | – | 2 | – | 1 | – | 1 | – | 2 | – | 2 | – | 2 | – |
| 97 | 7 | 0 | 7 | – | 6 | – | 6 | – | 6 | – | 7 | – | 6 | – | 7 | – |
| 101 | 1 | 0 | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – |
| 105 | 0 | 2 | – | 2 | – | 0 | – | 0 | – | 0 | – | 2 | – | 2 | – | 2 |
| 109 | 3 | 0 | 3 | – | 3 | – | 0 | – | 3 | – | 3 | – | 3 | – | 3 | – |
| 121 | 6 | 0 | 5 | – | 4 | – | 4 | – | 4 | – | 6 | – | 5 | – | 6 | – |
| 239 | 0 | 10 | – | 1 | – | 0 | – | 0 | – | 0 | – | – | – | 4 | – | 0 |
| 241 | 1 | 0 | 1 | – | 1 | – | 0 | – | 1 | – | 0 | – | 1 | – | 1 | – |
| 247 | 1 | 0 | 1 | – | 0 | – | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – |
| 398 | 1 | 0 | 1 | – | 1 | – | 1 | – | 1 | – | 0 | – | 1 | – | 1 | – |
| N.D. | 4 | 0 | 4 | – | 4 | – | 3 | – | 3 | – | 3 | – | 3 | – | 4 | – |
| Total of isolates (%) | 70 (53%) | 62 (47%) | 66 (94.3%) | 46 (74.1%) | 65 (92.9%) | 43 (69.3%) | 43 (61.4%) | 39 (62.9%) | 60 (85.7%) | 47 (75.8%) | 61 (87.1%) | 51 (82.3%) | 66 (94.3%) | 54 (87.1%) | 70 (100%) | 45 (72.6%) |
Fig. 1UPGMA dendrogram. The color code reflects MLVA clusters when using the 45% cutoff. ID: strain identification. PVL*: identification of PVL haplotype in selected isolates. MG: MLVA genotype. PS: population set.
Fig. 2Minimum spanning tree of the 132 S. aureus isolates. It represents the relationship of all isolates analyzed in this study. The different sequence types (ST) identified are represented in different colors. CC, clonal complex.